Key references: Atomoxetine for attention deficit hyperactivity disorder in children

Bolea-Alamanac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(3):179–203. https://www.ncbi.nlm.nih.gov/pubmed/24526134
Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 4th ed. Toronto, ON: CADDRA; 2018. http://www.caddra.ca/canadian-adhd-practice-guidelines/
Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag 2016;12:27–39. https://www.ncbi.nlm.nih.gov/pubmed/26730199
Feldman ME, Charach A, Belanger SA. ADHD in children and youth: Part 2-Treatment. Paediatr Child Health 2018;23(7):462–72. https://www.ncbi.nlm.nih.gov/pubmed/30681665
Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006;40(6):1134–42. https://www.ncbi.nlm.nih.gov/pubmed/16735655
National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management (NG87). London: NICE; 2018. https://www.nice.org.uk/guidance/NG87
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2019;144(4). https://www.ncbi.nlm.nih.gov/pubmed/31570648